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Abstract 27 
Inflammatory diseases such as inflammatory bowel disease (IBD) require recurrent invasive 28 
tests, including blood tests, radiology, and endoscopic evaluation both to diagnose and assess 29 
disease activity, and to determine optimal therapeutic strategies. Simple ‘bedside’ biomarkers 30 
could be used in all phases of patient management to avoid unnecessary investigation and 31 
guide further management. The focal adhesion complex (FAC) has been implicated in the 32 
pathogenesis of multiple inflammatory diseases, including IBD, rheumatoid arthritis, and 33 
multiple sclerosis. Utilizing omics technologies has proven to be an efficient approach to 34 
identify biomarkers from within the FAC in the field of cancer medicine. Predictive 35 
biomarkers are paving the way for the success of precision medicine for cancer patients, but 36 
inflammatory diseases have lagged behind in this respect. This review explores the current 37 
status of biomarker prediction for inflammatory diseases from within the FAC using omics 38 
technologies and highlights the benefits of future potential biomarker identification 39 
approaches. 40 
  41 
KEYWORDS: Focal adhesion complex; Biomarkers; Inflammation; Omics; Systems biology 42 
  
3 
Introduction 43 
Disease biomarkers have the potential to be medically valuable at all stages of the disease 44 
process from diagnosis, identification of disease subtypes, and prognosis to therapeutic 45 
adjustment. Inflammatory bowel disease (IBD) is an exemplar of a chronic, complex 46 
inflammatory disease. IBD has two major subtypes, ulcerative colitis (UC) and Crohn’s 47 
disease, which have different clinical courses and management strategies with a wide 48 
phenotypic variability among patients. Figure 1 highlights the points at which biomarkers 49 
have potential use in IBD.  50 
Biomarkers need to be specific, stable, and consistent across multiple platforms of testing 51 
in order to be used as a clinical application. This raises challenges associated with biomarker 52 
identification in IBD, as with any complex inflammatory condition, partly due to our limited 53 
understanding of the pathogenesis of these diseases and poor appreciation of the difference 54 
between what is healthy and what is a disease process. Hypothesis-driven biomarker 55 
discovery via traditional one protein−one metabolite or one cell analysis from cellular disease 56 
models or tissues compared between control and disease samples is laborious. Such an 57 
approach is also limited by the fact that gene expression and signalling of tissues depends on 58 
the context and their native environments [1]. For this reason, very few biomarkers make it to 59 
clinical practice [2]. Further challenges posed by complex diseases are that they often need to 60 
be stratified into sub-phenotypes via patients’ genetic features, which need to be taken into 61 
account, making identification of a broad generalizable biomarker difficult [3]. High 62 
throughput, hypothesis-free techniques are required for biomarker discovery. With the advent 63 
of high-throughput omics technologies and advances in computational biology, researchers 64 
are now able to generate, analyze, and interpret a variety of datasets and apply them on 65 
biomarker discovery at a scale, which were previously impossible (Figure 2). One of the 66 
cellular signal transduction pathways supplying candidate biomarkers that have become 67 
prominent through the use of omics technologies and computational biology, certainly for the 68 
cancer field, is the focal adhesion complex (FAC).  69 
FACs are dynamic, large protein assemblies that mechanically link and transduce signals 70 
from the extracellular matrix to the intracellular milieu via integrins [4] or other receptor 71 
modules such as cluster of differentiation 47 (CD47). The complex consists of core structural 72 
proteins such as paxillin, talin, actinin, and vinculin, with dynamic signalling proteins 73 
including protein kinases, phosphatases, small guanosine triphosphatases (GTPases) with 74 
regulatory molecules, and adapter molecules that mediate core protein−protein interactions 75 
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(Table 1). The ‘adhesome’ network contains 156 components with 690 interactions between 76 
them [26], highlighting the complexity of the focal adhesion function.  77 
The focal adhesion function is both mechanical and responsive. It is mechanical in terms 78 
of anchoring the cell to the extracellular matrix via binding of integrins to their extracellular 79 
ligands and to the actin cytoskeleton to modify the physical and topographical characteristics 80 
of the cell. This has direct implications for wound healing as well as invasion and the 81 
metastatic nature of the cancer cell. The responsive function of the FAC is diverse and multi-82 
layered. Depending on the initiating signal, FAC can be involved in regulating inflammatory 83 
gene expression via signal transduction pathways such as interleukin 1 (IL-1) signalling 84 
[27,28] or regulating calcium fluxes via phosphatidyl inositol signalling [29], which impact 85 
on inflammatory cascades. Many molecules in the FAC are involved in downstream 86 
signalling pathways, for instance, the MAPK/ERK pathway [30], AKT1 [22], and Wnt 87 
signalling [31,32]. In this way, pathways impacted by the FAC are as varied as apoptosis 88 
[21], production of cellular protrusions [33], cell cycle progression [34], and cell proliferation 89 
[35].  90 
The number of publications listed in PubMed involving FAC (‘focal adhesion complex’) 91 
has had a 5-fold increase from 141 published in 1996 to 709 published in 2015. The role of 92 
FAC in cancer has been a consistent focus of approximately 44% of publications over the 93 
past 20 years (Figure 3). Given the critical roles that focal adhesions play in regulating cell 94 
structure, proliferation, survival, migration, and invasion, it is not surprising that this makes 95 
the complex a prime target for biomarker candidacy and drug targeting in cancer, which is 96 
reflected in the overrepresentation of papers with the terms ‘cancer’, ‘focal adhesion’, and 97 
‘biomarker’ from a cohort of ‘focal adhesion’ and ‘biomarker’ publication subset.  98 
Of the publications identified using the Medical Subject Headings (MeSH) terms 99 
‘cancer’, ‘focal adhesion’, and also adding ‘biomarker’, 39 out of 745 used bioinformatics 100 
approaches for biomarker identification. It is of note that all these 39 studies were published 101 
after 2007.  102 
The role of FAC in the pathobiology of inflammatory diseases such as IBD or 103 
rheumatoid arthritis (RA) has been less well exploited for biomarker discovery. However, the 104 
role of FAC in inflammatory diseases can be well illustrated in UC. UC is a relapsing-105 
remitting disease which causes ulceration of the lining of the large bowel and is thought to be 106 
a disease of the epithelial barrier [36]. The epithelial barrier is an immuno-mechanical barrier 107 
consisting of mucous layers, intestinal epithelial cells, and closely-residing immune cell 108 
populations. The mechanical barrier is provided in part by the enterocytes joined by 109 
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intercellular junctions, of which the tight junction is a major component. May et al. [37] 110 
identified that activation of focal adhesion kinase (FAK) is necessary for maintaining and 111 
repairing the epithelial barrier in cell culture via tight junctions. This was further examined 112 
by Khan et al. [38] in both T84 cell lines and surgical specimens from IBD patients. They 113 
demonstrated that activation of M1 muscarinic acetylcholine receptor augmented the 114 
recovery of epithelial barrier function via phosphorylation of FAK. Further evidence for the 115 
role of FAK in maintaining intestinal epithelial barrier function in the presence of pathogenic 116 
factors was highlighted by Guo and colleagues [39]. Utilizing intestinal epithelial cell 117 
cultures, they identified that gut-derived bacterial lipopolysaccharide induced tight junction 118 
permeability via the FAK/myeloid differentiation primary response gene 88 (MyD88)/IL1 119 
receptor pathway. GTPases such as Rac1 [40] and tyrosine phosphatase members of FAC 120 
have a role in regulation of the NACHT, LRR and PYD domains-containing protein 3 121 
(NLRP3; also known as cryopyrin) inflammasome [41], which mediates the release of IL-1 122 
and IL-18 from cells. IL-18 signalling drives the breakdown of barrier integrity in murine 123 
models of UC [42]. Further evidence of FAC involvement in inflammasome activation was 124 
provided by Thinwa et al. [43] who demonstrated that the initial signal for intestinal cell 125 
inflammasome activation in pathogen recognition is via integrins. It is interesting to note that 126 
NLRP3 was identified as a candidate gene for susceptibility of Crohn’s disease [44], whereas 127 
IL-1 has been put forward as a faecal marker of inflammation in UC [45]. 128 
The evidence described above has been hypothesis-driven, utilizing mainly cellular 129 
models to describe a pathogenic system. In this review we will consider the literature field of 130 
FAC in inflammatory diseases focusing on those utilizing a systems medicine approach, 131 
where omics data and computational biology are combined for potential biomarker 132 
identification.  133 
In the last two decades, omics technologies have made a great impact on medical 134 
research, turning biological research into a data-intensive science [46]. These high-135 
throughput methodologies are now routinely used to provide a top-down approach in 136 
understanding biological systems. The power of omics approaches in systems medicine is due 137 
to their ability to detect context (e.g., cell, disease, or treatment) specific data for a signaling 138 
system. The challenge of these approaches is that it often requires either a computational 139 
biology expert or familiarity with sophisticated computational software solutions to extract 140 
biological insights from the datasets [47]. A further complication is that genomic or 141 
transcriptomic data are often best interpreted in the context of the heterogeneous large-scale 142 
datasets that have already been deposited in publicly-available databases [47]. 143 
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 144 
Genomics 145 
Genomic approaches provide the highest number and variety of datasets on human diseases. 146 
These approaches include (1) whole-genome or whole-exome sequencing that identify 147 
genetic mutations or copy number variations; (2) genome-wide association studies (GWAS) 148 
used to identify genetic variants associated with a disease; (3) microarray or RNA-seq 149 
techniques for measuring the mRNA or microRNA (miRNA) expression of cells and 150 
comparing the levels between states (transcriptomics); and (4) epigenomics analyses focusing 151 
on, for example, DNA methylation and its change during differentiation, ageing, and cancer 152 
progression. To analyze the genomic datasets of complex diseases, the systems medicine 153 
approach is a highly-effective framework to understand the complexity. Disease-related 154 
genes may differ among affected individuals, but the affected pathway or network region is 155 
likely to be shared [47]. The identified disease-related genes can be used to list potential 156 
biomarkers by filtering those specifically relevant to a given disease or disease stage. 157 
In particular, the advent of GWAS identifying candidate susceptibility genes has opened 158 
the door to the pathobiology of chronic inflammatory disease. With this, the prospect of a 159 
genetic marker for disease diagnosis, prognosis, and therapeutic efficacy in what can 160 
otherwise be very heterogeneous diseases is very appealing. GWAS in large populations of 161 
patients with chronic inflammatory diseases such as RA can identify common genetic 162 
variants that are associated with having that disease [48]. 163 
Zhang et al. [49] undertook analysis of the KEGG pathways [50] affected by 11,922 164 
differentially-expressed genes (DEGs), which had been identified by genome-wide 165 
association scans in RA patients. The focal adhesion and extracellular matrix receptor 166 
interaction pathways were considered high risk RA pathways. Core members of FAC with 167 
genetic variants included integrin subunits A and B, actinin, dedicator of cytokinesis 1 168 
(DOCK1), and B cell lymphoma 2 (BCL2). Their data correlate well with the DNA 169 
methylome signature in RA, comprising genome-wide DNA methylation loci from fibroblast-170 
like synoviocytes removed at the time of joint replacement from five patients with 171 
osteoarthritis and six patients with RA [49]. Nakano et al. [51] undertook global methylation 172 
status analysis and identified differential methylation between osteoarthritis and RA in 1206 173 
different genes. Differentially-methylated genes were mapped to KEGG pathways for gene 174 
ontology, which highlighted hypomethylation enrichment in the RA sample in loci including 175 
genes encoding integrin subunits A and B, actinin, receptor tyrosine kinases, parvin, DOCK1, 176 
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and BCL2. Hypomethylation of inflammatory genes has been associated with an increased 177 
inflammatory response, as hypomethylation in promoter regions of a gene makes it 178 
transcriptionally active [52,53]. 179 
Utilizing GWAS-mapped genes or methylome signatures alone for biomarker prediction 180 
has its limitations. Firstly, the differential expression of said genes is not assessed. Secondly, 181 
the presence or absence of a single polymorphism within a gene may not have a strong 182 
enough phenotype to be a useful biomarker [54]. Moreover, the use of methylation status as a 183 
biomarker is currently plagued by inaccuracy and poor replication, as there is a need for 184 
standardized methods and controls [55]. 185 
To overcome the potential limitation of not taking into account differential gene 186 
expression, He et al. [56] examined the Gene Expression Omnibus (GEO) microarray data to 187 
assess mRNA expression in the specific cell type involved in RA, synovial fibroblasts, to 188 
identify DEGs by comparing six RA patients to osteoarthritis patients (an age related, non-189 
autoimmune arthritis) using the linear models for microarray analysis (LIMMA) [57]. The 190 
authors undertook functional enrichment of the DEGs using KEGG pathways, with the 191 
analysis performed using the database annotation visualization and integrated discovery 192 
(DAVID) [58]. Using STRING [59], they created a larger protein−protein interaction (PPI) 193 
network for a further functional enrichment, looking for functional complexes using the 194 
MCODE plugin for Cytoscape [60]. This multi-layered approach comparing the two types of 195 
arthritis identified DEGs for collagen (a predominant member of the extracellular matrix) that 196 
were enriched in focal adhesion pathways and extracellular matrix receptor interactions for 197 
osteoarthritis, but not RA. The difficulty of biomarker identification based on gene 198 
expression studies only is that the studies are often small, thereby not taking into account the 199 
rich genetic variability of these complex diseases, and neither gene regulation nor protein 200 
levels of DEGs.  201 
 202 
Transcriptomics  203 
Combinatorial approaches utilizing DEGs and their regulation have been more successful for 204 
biomarker discovery. One mechanism of gene regulation is via small non-coding RNAs 205 
(ncRNAs) such as miRNAs. miRNAs function in RNA silencing, by base pairing binding of 206 
complementary sequences in mRNAs, thus targeting them for cleavage [61]. In the field of 207 
oncology, integrating miRNA, gene expression, and transcription factor signatures has been 208 
used to identify biomarkers for papillary thyroid cancer by using pathway enrichment to 209 
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identify dysregulated pathways including in focal adhesion [62]. Such approach of integrating 210 
miRNA data and differential gene expression for identification of molecular prognostic 211 
biomarkers was taken further by Cai and colleagues [63], who identified three potential 212 
biomarkers, CALM2, miR-19b, and miR181b, for gastric cancer that were related to the FAC 213 
and the extracellular matrix receptor. This integrative approach has been, however, less 214 
widely used in inflammatory models. For IBD [64] and many other autoimmune diseases 215 
including Sjogren’s disease [65], we are still at the stage of documenting differential 216 
expression levels of miRNAs between disease and control cohorts.  217 
Therefore, despite the central role FAC plays in inflammatory diseases, the number of 218 
ncRNAs that could be used as potential biomarkers are still scarce. In the case of UC and 219 
Crohn’s disease, miRNAs are the most explored ncRNAs in the literature. There is 220 
experimental evidence showing elevated levels of specific miRNAs in active UC tissues and 221 
in serum [66] . 222 
In recent years, many computational methods emerged that allow the analysis of specific 223 
ncRNA–disease associations, predict such connections and select the ones most suitable for 224 
experimental validation. For example, heterogeneous graph inference for miRNA–disease 225 
association prediction (HGIMDA) [67] and improved random walk with restart for lncRNA-226 
disease association prediction (IRWRLDA) [68] are two viable, novel methods that could be 227 
potentially used to describe new targets. HGIMDA constructs a heterogeneous graph out of 228 
separate networks: a functional similarity network of miRNAs and a semantic similarity 229 
network of diseases, which in combination allowed predicting potential disease–miRNA 230 
associations. IRWRLDA uses an improved random walk with restart algorithm on a lncRNA 231 
similarity network to rank potentially useful candidate lncRNAs.  232 
 233 
Proteomics 234 
Protein biomarker identification is driven by better understanding of the disease processes 235 
and signalling pathways involved in perpetuation of pathogenic states. Combining large-scale 236 
mass spectrometry (MS)-based proteomics and biological network analysis has been 237 
fundamental in the understanding of signalling networks [69], so it stands to reason that using 238 
similar techniques may drive biomarker identification for the large datasets that have been 239 
proved by proteomic platforms. Like genomics and transcriptomics, biomarker discovery 240 
using proteomics has often involved proteome analysis with pathway enrichment. A good 241 
example of this is reported by Rukmangadachar and colleagues [70]. They differentiated 242 
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intestinal tuberculosis (TB) and ileal Crohn’s disease, utilizing MS-based proteome analysis 243 
on ileal biopsies of 15 patients, in combination with pathway enrichment using KEGG 244 
pathways and the PANTHER annotation resource, and identified biomarkers of both 245 
intestinal TB and Crohn’s disease. They were able to identify overexpressed proteins in 246 
Crohn’s disease patients compared to intestinal TB patients. These proteins were annotated to 247 
pathways such as the integrin signalling pathway, including a core FAC member, vinculin. 248 
However, the proteins they identified were unable to be validated as differential biomarkers 249 
in their 52-patient validation cohort using immunohistochemistry. This emphasises the point 250 
that a one-step, single-omics approach on a small cohort of patients, whilst identifying 251 
potential pathways, lacks the finesse to complete the biomarker discovery. 252 
 253 
Systems biology and focal adhesion – the promise for novel biomarker 254 
discovery 255 
Looking again at the cancer model, we can see that integrative approaches using both omics 256 
data and computational biology have been successful in producing panel biomarkers for 257 
cancer subtypes. A good example of this is reported by Zhang and colleagues [71]. They took 258 
a systems biology approach to discover, characterize, and validate a panel of breast cancer 259 
biomarkers from breast cancer proteomics data. Using liquid chromatography (LC)-coupled 260 
MS data from 40 women with breast cancer and 40 women without breast cancer, they 261 
identified statistically significant differentially-expressed proteins. They further identified 262 
PPI networks and performed pathway analysis with significant literature curation 263 
(hypothesis-driven). As a result, they identified a panel of 25 breast cancer biomarkers, which 264 
were able to be validated against other proteomic datasets. The top three pathways they 265 
identified for the biomarker panel were focal adhesion, regulation of the actin cytoskeleton, 266 
as well as complement and coagulation cascades. Combining gene expression data with PPI 267 
networks and analysis by a computation network method that utilizes PPI affinity has been 268 
equally successful in another breast cancer biomarker discovery study. Protein interactors 269 
specific for metastatic breast cancer were identified, which unsurprisingly are part of FAC 270 
[72]. Like in cancer, FAC has clearly been implicated in the pathogenesis of complex 271 
inflammatory diseases including RA [73] and IBD, leading to the tantalizing possibility of 272 
clinical biomarkers identified from within the ranks of FAC.  273 
Utilizing single omics technologies with computation biology has provided potential 274 
markers, but these have often failed to stand up to rigorous validation due to small sample 275 
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sizes, differences in tissues sampled, or methodological differences. Perhaps a more holistic, 276 
integrated approach is needed to meet the needs of modern medicine. This approach towards 277 
a more systemic view necessitates obtaining significant insights by adopting a variety of 278 
complementary approaches, such as (1) genomics and transcriptional profiling (including 279 
miRNA and lncRNA analysis); and (2) functional and phospho-proteomics (affinity 280 
purification and MS), as well as other types of large-scale studies, including lipidomics 281 
(isolation and MS analysis of lipid content and protein−lipid interactions), chemical 282 
proteomics, and compound screening. With the combined and integrated use of these omics 283 
approaches, we can identify potential novel biomarkers and drug targets. All biomarkers to be 284 
used in clinical practice need independent validation with clinical samples. One such way as 285 
used by Szasz et al. [74] is to merge transcriptomic data from multiple independent datasets 286 
to cross validate gene expression biomarkers using univariate and multivariate analyses in 287 
1065 patients. Where such samples are not available or not appropriate, clinical trials with 288 
patient cohorts need to be undertaken comparing the biomarker candidates identified against 289 
a gold standard. An example of this can be seen in Brandse et al. [75] comparing an 290 
inflammatory marker, fecal calprotectin, against the gold standard of leukocyte scintigraphy 291 
for denoting inflammatory burden in UC. 292 
 293 
Conclusions 294 
The FAC is a large, dynamic, multimeric structural and signalling opportunity for biomarker 295 
identification. Cancer research has led the way with FAC members being implicated as 296 
biomarkers of invasion [76], differentiation between normal and cancer cells [77], prognosis 297 
[78], and diagnosis [63]. It is clear that the FAC has a role to play in many inflammatory 298 
diseases. However, which member, by which mechanism (be it genomic, transcriptomic, 299 
proteomic, or a combinatorial approach with a panel of biomarkers [79]) and in which cell 300 
type, remains to be formally validated. Here we presented a few examples of how omics 301 
approaches could be exploited, separately or in combination, to provide valuable novel 302 
biomarkers for inflammatory diseases from members of the FAC that can undergo further 303 
validation in a clinical trial. 304 
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Figure legends 531 
Figure 1  Potential sites of biomarker used in IBD  532 
IBD-U refers to IBD-undefined, for which the patient’s endoscopy and histology cannot give 533 
a clear distinction between UC and CD. IBD, inflammatory bowel disease; UC, ulcerative 534 
colitis; CD, Crohn’s disease. 535 
 536 
Figure 2  Omics approaches with complementary potential to be integrated 537 
Genomics, transcriptomics, and proteomics approaches can be used to identify and discover 538 
the detailed component, mechanisms, and regulation of the FAC members in normal and in 539 
diseased states. The differential analysis is capable to point out novel biomarkers. FAC, focal 540 
adhesion complex; GWAS, genome-wide association studies; MS, mass spectrometry; WES, 541 
whole-exome sequencing; WGS, whole-genome sequencing. 542 
 543 
Figure 3  Biomarker related publications about focal adhesion complex 544 
We compared the total publications in PubMed identified with MeSH terms ‘focal adhesion 545 
and biomarker’ with ‘cancer, focal adhesion and biomarker’ from the last 20 years. The 546 
figure highlights the unchanged and low number of biomarker-related studies involving the 547 
FAC and non-cancer diseases compared to cancer related studies. FAC, focal adhesion 548 
complex. 549 
 550 
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Table 1  Component examples of the focal adhesion complex 563 
Category Example  Function Refs. 
Actin binding Actinin1, filamin A, 
cortactin, zyxin 
Crosslink actin; remodel 
cytoskeleton 
[5,6] 
Adapter SORBS1, ABI1 Link proximal signal 
pathways; facilitate signal 
transduction 
[7,8] 
Cytoskeletal Actin, vinculin, plectin, 
ezrin, paxillin 
Facilitate and stabilize 
signalling platforms; remodel 
cell shape and movement 
[9,10] 
GAP/GEF DOCK1, ELMO1 Activate small GTPases [11] 
GTPase Rac1, RhoA Signal cytoskeletal 
remodelling, cell growth, 
phagocytosis, and ruffled 
borders 
[12] 
Metalloproteinase ADAM12 Disintegrin [13] 
PIK/phosphatase PI3K, INPPL1, PTEN Regulate AKT/PKB 
signalling pathway; regulate 
signalling via IRS proteins 
[14,15] 
Receptor Integrins, IL1R, CD47 Bind to ligands for 
extracellular matrix 
constituents including 
fibronectin and 
thrombospondin 
[16,17] 
Serine/threonine 
kinase 
PAK1, AKT, PRKCA Effectors linking Rho 
GTPases to cytoskeletal 
reorganization; 
phosphorylate BCL2 
[15,18] 
Transcription factor ITGB3BP Transcriptional co-regulator [19] 
Tyrosine kinase FAK, SYK, SRC Regulate FAC assembly and 
disassembly 
[20–22] 
Tyrosine 
phosphatase 
PTPN1, 2, 6, 11, 12, 22, 
PTP-PEST 
Regulate maturation of focal 
adhesion; recruit signalling 
molecules 
[23–25] 
Note: GTPase, guanosine triphosphatase; GAP, GTPase activating protein; GEF, 564 
guanine nucleotide exchange factor; PIK, phosphoinositide kinase; SORBS1, sorbin and 565 
SH3 domain-containing 1; ABI1, Abelson interactor 1; DOCK1, dedicator of cytokinesis 566 
protein 1; ELMO1, engulfment and cell motility protein 1; Rac1, Ras-related C3 botulinum 567 
toxin substrate 1; RhoA, Ras homolog gene family, member A; ADAM12, disintegrin and 568 
metalloproteinase domain-containing protein 12; PI3K, phosphatidyl-inositol-3-kinase; 569 
INPPL1, inositol polyphosphate phosphatase like 1; PTEN, phosphatase and tensin homolog; 570 
IL1R, interleukin-1 receptor type 1; CD47, Cluster of Differentiation 47; PAK1, 571 
serine/threonine-protein kinase 1; AKT, RAC-alpha serine/threonine-protein kinase; PRKCA, 572 
protein kinase C alpha type; ITGB3BP, integrin subunit beta 3 binding protein; FAC, focal 573 
adhesion complex; FAK, focal adhesion kinase; SYK, spleen tyrosine kinase; SRC, proto-574 
oncogene tyrosine-protein kinase; PTPN, tyrosine-protein phosphatase non-receptor type; 575 
PTP, protein tyrosine phosphatase; PKB, protein kinase B; Bcl2, B-cell lymphoma 2. 576 
 577 
